We are live on ! Find out more

Rocket Pharmaceuticals

RCKT

Market cap $407M

3.71 USD

-0.15

3.89%

At close Updated Sep 8, 4:00 PM EDT

1 day

-3.89%

5 days

-0.27%

1 month

1.92%

3 months

37.41%

6 months

-27.4%

Year to date

7.23%

1 year

13.8%

5 years

-89.12%

10 years

-87.14%

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 202

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 71.4%

Negative 0%

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in New York. Gaurav Shah, M.D., Chief Executive Officer, will take part in fireside chats.

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Zacks Investment Research

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened Rocket's position, with the approval of KRESLADI demonstrating our ability to advance a genetic medi.

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on Monday shared a clinical safety update concerning the first three patients treated in its global, pivotal Phase 2 trial for Danon disease.

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease. Early safety has been promising with t.

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI.

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside ch.

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Zacks Investment Research

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

See News Rankings

Price charts implemented using Lightweight Charts™